Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265350 | 0.95 | ADRB2 (0.45) | ABCB1CA12CA1CA2CA9 | |
| SCHEMBL4887668 | 0.93 | ADRB2 (0.43) | ABCB1ADRB2ADRB1CYP1A2CYP3A4 | |
| SCHEMBL4881168 | 0.93 | LMNA (0.41) | ABCB1ADRB2ADRB1CYP1A2CYP3A4 | |
| SCHEMBL5630730 | 0.92 | MAPT (0.44) | ABCB1ADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL5631067 | 0.92 | MAPT (0.44) | ABCB1ADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL4888994 | 0.91 | CA12 (0.43) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL4884792 | 0.90 | MAPT (0.39) | ABCB1ADRB2ADRB1CYP2D6CYP1A2 | |
| SCHEMBL4881191 | 0.89 | ADRB1 (0.49) | ADRB2ADRB1CYP2D6CYP1A2GAA | |
| SCHEMBL4890684 | 0.87 | ADRB2 (0.38) | ADRB2ADRB1CYP2D6CYP3A4 | |
| SCHEMBL5633240 | 0.86 | LMNA (0.41) | ADRB2ADRB1CYP2D6CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | claimed |
| EP-1830852-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006060127-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1830852-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006060127-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ADRB3, PDE3A, PDE3B | ABCB1 947/4885CA12 2764/4885CA1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.